MindWalk Holdings Corp. filings document a foreign private issuer that furnishes Form 6-K reports for U.S. market disclosure. The company’s regulatory record includes earnings releases, IFRS-tagged financial data, press releases on Bio-Native AI platform developments, and exhibits covering technologies such as LensAI, HYFT, and B Cell Llama.
The filings also disclose capital-structure and governance items, including issued capital, restricted share units, stock options, lease liabilities, product sales, internally generated development costs, and corporate segment data. Separate 6-K submissions provide SEDI insider activity reports, reflecting the company’s foreign private issuer treatment and exemption from Section 16 Form 4 reporting requirements.
MindWalk Holdings Corp. (HYFT) scheduled its annual general meeting for November 17, 2026, by live webcast. Shareholders will consider electing four directors and appointing Davidson & Company LLP as auditor for the ensuing year. The audited fiscal 2026 statements will be presented for receipt, with no shareholder vote. As of October 13, 2026, 47,574,512 Common Shares were issued and outstanding, with one vote per share; management recommends voting for each director nominee and the auditor appointment.
For the year ended April 30, 2026, reported total compensation was C$2,121,330 for CEO Dr. Jennifer L. Bath, C$718,095 for CFO R. Scott Areglado, and C$791,970 for Chief Business Officer Dr. Thomas Lynch. Dr. Lynch’s employment agreement was terminated on October 16, 2026, and he ceased being an officer that day. The Stock Incentive Plan authorizes 5,620,254 Common Shares; 4,335,226 shares remained available for future issuance as of April 30, 2026.
MindWalk Holdings Corp. announced that Thomas Lynch, PhD, departed and ceased serving as Chief Business Officer effective October 16, 2026. The commercial and business development team continues to report to Chief Executive Officer and President Jennifer Bath, PhD.
MindWalk said its commercial priorities remain delivering on platform deployments already under contract and advancing pharma and partner engagements in progress. It said LensAI, its reasoning and application layer, is in contracted, recurring arrangements with life sciences customers and runs on ReefIQ, the biological data substrate powered by HYFT Technology. MindWalk describes its HYFT fingerprints as spanning sequence and structural biology and, refined over 20 years of curation, forming a representation of 660 million patterns and 25 billion relationships.
MindWalk Holdings Corp. reported benchmark results for LensAI™ immunogenicity screening on Amazon EC2 Hpc8a instances powered by AMD EPYC processors. The system screened 890,634 sequences in the Fitness Landscape for Antibodies database in 4 hours and 41 minutes, and 348,550 sequences in the Patent and Literature Antibody Database in 2 hours and 12 minutes.
Compared with an Amazon EC2 C8i configuration powered by Intel Xeon processors, the benchmark recorded 37% faster performance and approximately 43% lower cost per sequence. An Amazon EC2 C8a configuration recorded 35% faster performance and approximately 29% lower cost per sequence. The tests used identical code, were repeated five times and averaged; results reflect the configurations evaluated and are not representative of all workloads. LensAI immunogenicity screening is commercially available from MindWalk.
MindWalk Holdings Corp. (HYFT) announced three senior appointments and expanded responsibilities for its Boston-based development leadership as its pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director, Antigen Discovery & Protein Engineering, and Joanne Lim, PhD, joins as Director, Preclinical Development. Shuji Sato, PhD, MindWalk’s Vice President, Innovative Solutions, expands his responsibilities to include the pipeline. Maben will lead antigen discovery and protein engineering across the pipeline; Lim will provide preclinical development leadership and contribute to asset evaluations, in-licensing assessments and partnership discussions. The company says Sato’s expanded role will include pipeline prioritization and positioning. Their backgrounds include roles at Arbor Biotechnologies, Orum Therapeutics, Pfizer, Novartis and other biotechnology companies. MindWalk says the leadership team will support evaluation of pipeline programs and external opportunities as preclinical efficacy data emerge.
MindWalk Holdings Corp. outlined ReefIQ™ as a biological context layer for life sciences, powered by its HYFT® Technology. The company says HYFT encodes biology as function-aware pattern-objects and forms a representation of 660 million patterns and 25 billion relationships, refined over 20 years of curation. ReefIQ has been commercially available since June 2026, while LensAI is in contracted, recurring arrangements with life sciences clients.
MindWalk says ReefIQ enriches client discovery data as it enters the platform and provides governed context for models and agents. Licensing is metered on the data a client holds and the compute it runs. Deployments typically begin with data management and widen into analytical tools and custom models.
MindWalk Holdings Corp. (HYFT) appointed Kim Remizowski as an independent director, effective September 29, 2026. He will serve on the Audit Committee and the Compensation, Nomination and Governance Committee. The board determined that he qualifies as an independent director under Nasdaq listing rules, and the accompanying announcement identifies him as an audit committee financial expert under applicable SEC rules.
Remizowski has more than 35 years of institutional banking and fiduciary oversight experience. His prior roles include Director, Private Equity at Vistra, Managing Director at DMS Bank & Trust Ltd., and 17 years at Royal Bank of Canada. He is a Licensed Director with the Cayman Islands Monetary Authority and an Accredited Director of the Chartered Governance Institute of Canada.
MindWalk Holdings Corp. (HYFT) scheduled an Annual General Meeting of security holders as a virtual meeting on November 17, 2026. The record date for notice, voting, and beneficial ownership determination is October 13, 2026. The company will not use Notice and Access and will not send proxy materials directly to NOBOs or pay for delivery to OBOs.
MindWalk Holdings Corp. (HYFT) reported a production deployment of the open-source OpenFold3 structure prediction model using AMD Inference Microservices on Vultr Kubernetes Engine with AMD Instinct MI325X GPUs. In MindWalk's own workloads, antibody-antigen inference ran about 5x faster than in its prior environment, with a production-grade prediction stack deployed in minutes.
The deployment expands compute capacity beneath ReefIQ™, MindWalk's biological context layer, and is positioned as independent validation of AMD Inference Microservices for OpenFold3 in a life sciences setting. MindWalk emphasized that value in its platform accrues primarily in its proprietary HYFT® biological representation, which underpins ReefIQ and the LensAI™ reasoning layer for discovery and portfolio decision support.
MindWalk Holdings Corp. (HYFT) reported fiscal first quarter 2027 revenue of $3.8 million, up 21% year over year, with gross profit rising 47% to $2.2 million and gross margin expanding to 58.6% from 48.3%. The quarter marked the commercial launch of its ReefIQ™ data platform and a shift toward recurring, platform-based revenue.
Operating expenses increased to $8.4 million from $5.7 million, driven mainly by higher sales and marketing and non-cash share-based compensation, leading to a larger operating loss of $6.1 million. Net loss from continuing operations was $6.1 million, or $0.13 per share, compared with $4.1 million, or $0.09 per share. Net cash used in operating activities was $4.0 million, modestly improved from $4.2 million, and cash stood at $7.6 million as of July 31, 2026.
Subsequent to quarter-end, MindWalk received a binding commitment for a US$30 million senior unsecured revolving credit facility at a fixed 7.00% rate, with no financial maintenance covenants, no warrants or conversion feature, and no asset pledge, intended to support ReefIQ™ and LensAI™ enterprise onboarding and the transition to recurring, platform-based revenue without equity dilution.
MindWalk Holdings Corp. (HYFT), a Bio-Native AI drug discovery company, reported higher revenue but deeper losses for the three months ended July 31, 2026. Revenue from continuing operations was $3.8 million, up 21.3% from the prior-year quarter, driven mainly by higher project revenue. Gross profit rose to $2.2 million with a gross margin of 59%, compared with 48% a year earlier, as cost of sales remained relatively flat.
Operating expenses increased to $8.4 million from $5.7 million, largely due to higher sales and marketing, general and administrative, and share-based compensation, resulting in a larger net loss from continuing operations of $6.1 million versus $4.1 million. Cash and restricted cash declined to $7.8 million from $11.5 million at April 30, 2026. Management states that existing cash is not sufficient to fund operations for at least one year, raising substantial doubt about the company’s ability to continue as a going concern without additional financing. A previously identified material weakness in internal control over financial reporting related to complex technical accounting remains unremediated, although remediation efforts are ongoing.